ASCO white blood cell growth factor guidelines
Updated guidelines from the American Society of Clinical Oncology lower the recommended risk level for when cancer patients at risk of febrile neutropenia should receive hematopoietic colony stimulating factors. The new guidelines recommend CSF use when the risk of febrile neutropenia is 20% or greater. It was previously 40%. Amgen's Neulasta (pegfilgrastim) and Neupogen (filgrastim) as well as Schering AG's Leukine (sargramostim) are used in cancer treatment-induced febrile neutropenia. Amgen does not expect the guidelines to affect reimbursement for Neulasta since payers already reimburse based on a recent labeling update allowing treatment at the 17% febrile neutropenia risk level...
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.